SCHEMBL23907992

SCHEMBL23907992

CS(=O)(=O)c1nc(OCC(=O)NC23CC4CC(CC(C4)C2)C3)cc(Oc2ccc(F)cc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 4/20 0.46
ALDH1A1 P00352 6/20 0.46
HPGD P15428 2/20 0.46
TSHR P16473 1/20 0.46
PTPRC P08575 1/20 0.44
PTPN1 P18031 1/20 0.44
PTPN11 Q06124 1/20 0.44
PTPN13 Q12923 1/20 0.44
PTPN22 Q9Y2R2 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 3/20 0.41
LMNA P02545 2/20 0.41
THRB P10828 1/20 0.41
VDR P11473 1/20 0.41
NPC1 O15118 2/20 0.41
NPSR1 Q6W5P4 1/20 0.40
MDH1 P40925 1/20 0.39
MDH2 P40926 1/20 0.39
PDE2A O00408 1/20 0.39
PDE3B Q13370 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23908003 0.86 EPHX2 (0.47) EPHX2ALDH1A1HPGDTSHRPTPRC
SCHEMBL23884309 0.84 LMNA (0.48) ALDH1A1HPGDTSHRPTPRCPTPN1
SCHEMBL23900370 0.79 EPHX2 (0.47) EPHX2ALDH1A1HPGDTSHRPTPRC
SCHEMBL30361601 0.78 SCN9A (0.41) ALDH1A1L3MBTL1MAPTLMNANPC1
SCHEMBL23907999 0.75 ALDH1A1 (0.41) EPHX2ALDH1A1HPGDTSHRPTPRC
SCHEMBL30165253 0.75 SCN9A (0.38) EPHX2
SCHEMBL23884144 0.75 SCN9A (0.38) EPHX2
SCHEMBL23884289 0.73 ALDH1A1 (0.42) ALDH1A1HPGDTSHRPTPRCPTPN1
SCHEMBL30165249 0.73 ALDH1A1 (0.42) ALDH1A1HPGDTSHRPTPRCPTPN1
SCHEMBL23900443 0.73 PTPRC (0.42) EPHX2ALDH1A1HPGDTSHRPTPRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240182450-A1 Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses OREGON HEALTH AND SCIENCE UNIVERSITY 2024-06-06 US disclosed
US-11932626-B2 2-pyrimidone analogs as potent antiviral agents against Alphaviruses SOUTHERN RESEARCH INSTITUTE (US) 2024-03-19 US disclosed
US-20230120566-A1 Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses OREGON HEALTH AND SCIENCE UNIVERSITY 2023-04-20 US disclosed
US-20230120566-A1 Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses OREGON HEALTH AND SCIENCE UNIVERSITY 2023-04-20 US disclosed
CN-115916175-A Novel 2-pyrimidinone analogs as potent antiviral agents against alphaviruses 南方研究院 2023-04-04 CN disclosed
EP-4125845-A1 NOVEL 2-PYRIMIDONE ANALOGS AS POTENT ANTIVIRAL AGENTS AGAINST ALPHAVIRUSES Southern Research Institute (US) 2023-02-08 EP disclosed
US-11566019-B2 2-pyrimidone analogs as potent antiviral agents against alphaviruses SOUTHERN RESEARCH INSTITUTE (US) 2023-01-31 US disclosed
US-11566019-B2 2-pyrimidone analogs as potent antiviral agents against alphaviruses SOUTHERN RESEARCH INSTITUTE (US) 2023-01-31 US disclosed
US-20220177452-A9 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-06-09 US disclosed
US-20220177452-A9 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-06-09 US disclosed
US-20210317106-A1 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses SOUTHERN RES INST (US) 2021-10-14 US disclosed
US-20210317106-A1 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses SOUTHERN RES INST (US) 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317106-A1 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses EIF2AK2, ZC3HAV1, MAVS EPHX2 645/4885ALDH1A1 492/4885HPGD 1775/4885
US-11566019-B2 2-pyrimidone analogs as potent antiviral agents against alphaviruses EIF2AK2, ZC3HAV1, MAVS EPHX2 645/4885ALDH1A1 492/4885HPGD 1775/4885
US-11932626-B2 2-pyrimidone analogs as potent antiviral agents against Alphaviruses EIF2AK2, ZC3HAV1, MAVS EPHX2 645/4885ALDH1A1 492/4885HPGD 1775/4885
US-20220177452-A9 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses EIF2AK2, ZC3HAV1, MAVS EPHX2 645/4885ALDH1A1 492/4885HPGD 1775/4885
US-20240182450-A1 Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses EIF2AK2, ZC3HAV1, MAVS EPHX2 608/4885ALDH1A1 589/4885HPGD 2020/4885
US-20230120566-A1 Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses EIF2AK2, ZC3HAV1, MAVS EPHX2 608/4885ALDH1A1 589/4885HPGD 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.